Cargando…

Targeted therapy in severe asthma today: focus on immunoglobulin E

Asthma is a complex chronic inflammatory disease of multifactorial etiology. International guidelines increasingly recognize that a standard “one size fits all” approach is no longer an effective approach to achieve optimal treatment outcomes, and a number of disease phenotypes have been proposed fo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pelaia, Girolamo, Canonica, Giorgio Walter, Matucci, Andrea, Paolini, Rossella, Triggiani, Massimo, Paggiaro, Pierluigi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5500555/ https://www.ncbi.nlm.nih.gov/pubmed/28721017 http://dx.doi.org/10.2147/DDDT.S130743

Ejemplares similares

Interleukin-5 in the Pathophysiology of Severe Asthma
por: Pelaia, Corrado, et al.
Publicado: (2019)

Sex Differences in Severe Asthma: Results From Severe Asthma Network in Italy-SANI
por: Senna, Gianenrico, et al.
Publicado: (2020)

Shadow cost of oral corticosteroids-related adverse events: A pharmacoeconomic evaluation applied to real-life data from the Severe Asthma Network in Italy (SANI) registry
por: Canonica, Giorgio Walter, et al.
Publicado: (2019)

Patient and physician perspectives on biological treatment in severe asthma: a Severe Asthma Network Italy survey
por: Crimi, Claudia, et al.
Publicado: (2023)

Frequency of Tiotropium Bromide Use and Clinical Features of Patients with Severe Asthma in a Real-Life Setting: Data from the Severe Asthma Network in Italy (SANI) Registry
por: Puggioni, Francesca, et al.
Publicado: (2020)

Manifesto on the overuse of SABA in the management of asthma: new approaches and new strategies
por: Canonica, Giorgio Walter, et al.
Publicado: (2021)

Interleukins 4 and 13 in Asthma: Key Pathophysiologic Cytokines and Druggable Molecular Targets
por: Pelaia, Corrado, et al.
Publicado: (2022)

Overcoming Barriers to the Effective Management of Severe Asthma in Italy
por: Paggiaro, Pierluigi, et al.
Publicado: (2021)

Severe asthma: One disease and multiple definitions
por: Bagnasco, Diego, et al.
Publicado: (2021)

Role of biologics in severe eosinophilic asthma – focus on reslizumab
por: Pelaia, Girolamo, et al.
Publicado: (2016)

Defining type 2 asthma and patients eligible for dupilumab in Italy: a biomarker-based analysis
por: Canonica, Giorgio Walter, et al.
Publicado: (2021)

Real-World Experience with Benralizumab in Patients with Severe Eosinophilic Asthma: A Case Series
por: Menzella, Francesco, et al.
Publicado: (2021)

The World Allergy Organization Today
por: Walter Canonica, G
Publicado: (2008)

SANI-Severe Asthma Network in Italy: a way forward to monitor severe asthma
por: Senna, G., et al.
Publicado: (2017)

Benralizumab in the treatment of severe asthma: design, development and potential place in therapy
por: Pelaia, Corrado, et al.
Publicado: (2018)

Real-Life Effectiveness of Mepolizumab on Forced Expiratory Flow between 25% and 75% of Forced Vital Capacity in Patients with Severe Eosinophilic Asthma
por: Maglio, Angelantonio, et al.
Publicado: (2021)

Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life()
por: Bagnasco, Diego, et al.
Publicado: (2021)

Biologics in Severe Eosinophilic Asthma: Three-Year Follow-Up in a SANI Single Center
por: Solidoro, Paolo, et al.
Publicado: (2022)

Biomarkers and severe asthma: a critical appraisal
por: Chiappori, Alessandra, et al.
Publicado: (2015)

Molecular Targets for Biological Therapies of Severe Asthma
por: Pelaia, Corrado, et al.
Publicado: (2020)

Relevance of Smoking Habit in Severe Asthma Patients: Evidence from the Severe Asthma Network in Italy (SANI) Registry
por: Caminati, Marco, et al.
Publicado: (2022)

Benralizumab in Patients with Severe Eosinophilic Asthma: A Multicentre Real-Life Experience
por: Scioscia, Giulia, et al.
Publicado: (2023)

The Hidden Burden of Severe Asthma: From Patient Perspective to New Opportunities for Clinicians
por: Scichilone, Nicola, et al.
Publicado: (2020)

Personalized Approach to Severe Asthma
por: Heffler, Enrico, et al.
Publicado: (2018)

Biologicals decrease psychological distress, anxiety and depression in severe asthma, despite Covid-19 pandemic
por: Patella, Vincenzo, et al.
Publicado: (2022)

Real-world characteristics of “super-responders” to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis
por: Portacci, Andrea, et al.
Publicado: (2023)

Therapeutic interventions in severe asthma
por: Canonica, Giorgio Walter, et al.
Publicado: (2016)

Omalizumab and cancer risk: Current evidence in allergic asthma, chronic urticaria, and chronic rhinosinusitis with nasal polyps
por: Bagnasco, Diego, et al.
Publicado: (2022)

Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab
por: Pelaia, Corrado, et al.
Publicado: (2017)

Short-Term Evaluation of Dupilumab Effects in Patients with Severe Asthma and Nasal Polyposis
por: Pelaia, Corrado, et al.
Publicado: (2021)

Is allergic sensitization relevant in severe asthma? Which allergens may be culprit?
por: Lombardi, Carlo, et al.
Publicado: (2017)

Personalized Management of Patients with Chronic Rhinosinusitis with Nasal Polyps in Clinical Practice: A Multidisciplinary Consensus Statement
por: De Corso, Eugenio, et al.
Publicado: (2022)

Omalizumab, the first available antibody for biological treatment of severe asthma: more than a decade of real-life effectiveness
por: Pelaia, Corrado, et al.
Publicado: (2018)

Nanobiotechnology today: focus on nanoparticles
por: Soloviev, Mikhail
Publicado: (2007)

Impact of baseline patient characteristics on dupilumab efficacy in type 2 asthma
por: Busse, William W., et al.
Publicado: (2021)

Benralizumab: From the Basic Mechanism of Action to the Potential Use in the Biological Therapy of Severe Eosinophilic Asthma
por: Pelaia, Corrado, et al.
Publicado: (2018)

Real-life effects of benralizumab on allergic chronic rhinosinusitis and nasal polyposis associated with severe asthma
por: Lombardo, Nicola, et al.
Publicado: (2020)

Treatment strategies for asthma: reshaping the concept of asthma management
por: Papi, Alberto, et al.
Publicado: (2020)

On-line Italian register for severe/non-controlled asthma
por: Bresciani, Megon, et al.
Publicado: (2013)

Immunoglobulin E Receptor Signaling and Asthma
por: Wu, Lawren C.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_emv8d7d7qfkimltd6q517jc792